234 related articles for article (PubMed ID: 20215370)
1. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis.
Lee RW; Dick AD
Br J Ophthalmol; 2010 Mar; 94(3):269-70. PubMed ID: 20215370
[No Abstract] [Full Text] [Related]
2. Anti-TNF-alpha therapy for uveitis: Behçet and beyond.
Murray PI; Sivaraj RR
Eye (Lond); 2005 Aug; 19(8):831-3. PubMed ID: 16086039
[No Abstract] [Full Text] [Related]
3. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
4. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
5. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
[No Abstract] [Full Text] [Related]
6. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
7. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
Kotter I; Deuter C; Stubiger N; Zierhut M
J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
[No Abstract] [Full Text] [Related]
8. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
9. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
11. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease.
Rosenbaum JT
J Rheumatol; 2004 Jul; 31(7):1241-3. PubMed ID: 15229938
[No Abstract] [Full Text] [Related]
12. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
[TBL] [Abstract][Full Text] [Related]
13. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents.
Celiker H; Kazokoglu H; Direskeneli H
BMC Ophthalmol; 2018 Oct; 18(1):261. PubMed ID: 30290779
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
15. Author reply: To PMID 24359625.
Read RW; Levy-Clarke G; Jabs DA; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Oct; 121(10):e58-9. PubMed ID: 25015217
[No Abstract] [Full Text] [Related]
16. Treatment of ocular manifestations of Behçet's disease.
Davatchi F
Adv Exp Med Biol; 2003; 528():487-91. PubMed ID: 12918750
[No Abstract] [Full Text] [Related]
17. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
19. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
Benitah NR; Sobrin L; Papaliodis GN
Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
[TBL] [Abstract][Full Text] [Related]
20. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha.
Evereklioglu C; Borlu M
Br J Ophthalmol; 2008 Aug; 92(8):1034, 1148-9. PubMed ID: 18653594
[No Abstract] [Full Text] [Related]
[Next] [New Search]
